Evidence map›Paper›PMID 38089156›Full record

ArticleMethodsX2024

Method for depletion of mitochondria DNA in human bronchial epithelial cells.

Michael V Novotny, Weiling Xu, Anny Mulya, Allison J Janocha, Serpil C Erzurum

Open access · goldAbstract read
In one paragraph

Article in MethodsX, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Discovery of novel disease-causing mutation inMolecular therapy. Nucleic acids · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michael V NovotnyLerner Research Institute, USA.
Weiling XuLerner Research Institute, USA.
Anny MulyaLerner Research Institute, USA.
Allison J JanochaLerner Research Institute, USA.
Serpil C ErzurumLerner Research Institute, USA.
Cerner (United States) · USCleveland Clinic · US

Funding

Targeting pathological hyaluronan matricesP01HL103453 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2011 to 2020
$26.8M
Tissue Processing and Cell Culture COreP01HL081064 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2006 to 2019
$17.8M
NITRIC OXIDE PRODUCTION AND REACTIONS IN THE LUNGR01HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI Serpil C. Erzurum · 1999 to 2026
$6.3M
Nitric Oxide in Pulmonary HypertensionR37HL060917 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI ERZURUM, SERPIL C. · 2009 to 2018
$3.9M
NHLBI NIH HHS P01 HL081064NHLBI NIH HHS P01 HL103453NHLBI NIH HHS R01 HL060917NHLBI NIH HHS R37 HL060917
6 · The paper itself

Abstract

Mitochondria are increasingly recognized to play a role in the airway inflammation of asthma. Model systems to study the role of mitochondrial gene expression in bronchial epithelium are lacking. Here, we create custom bronchial epithelial cell lines that are depleted of mitochondrial DNA. One week of ethidium bromide (EtBr) treatment led to ∼95 % reduction of mtDNA copy number (mtDNA-CN) in cells, which was further reduced by addition of 25 µM 2',3'-dideoxycytidin (ddC). Treatment for up to three weeks with EtBr and ddC led to near complete loss of mtDNA

Indexed as

BEAS-2BBronchial epithelial cells BET-1ADepletion of Mitochondria DNAMitochondrial DNAρ0 cells

Identifiers

PMID38089156
PMCPMC10711463
OpenAlexW4388980228

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.